TY  - JOUR
T1  - Assessment of tumor lysis syndrome cases
TT  - Tümör lizis sendromlu olguların değerlendirilmesi
AU  - Hüzmeli, Can
PY  - 2019
DA  - March
Y2  - 2019
DO  - 10.7197/223.vi.460369
JF  - Cumhuriyet Medical Journal
JO  - CMJ
PB  - Sivas Cumhuriyet University
WT  - DergiPark
SN  - 1305-0028
SP  - 28
EP  - 33
VL  - 41
IS  - 1
LA  - en
AB  - Objective: Tumor lysissyndrome (TLS) is a clinical picture that occurs with the rapid destruction oftumor cells and with life-threatening metabolic disorders. The aim of our studyis to evaluate the etiologic causes, diagnosis and treatment of TLS cases. Method: The study wasconducted between January 2015 and December 2017 in KahramanmarasNecip Fazıl city Hospital.[HT1]Atotal of 32 patients diagnosed with TLS were included in the study. Laboratoryvalues of patients were scanned (blood urea nitrogen, creatinine, potassium,phosphorus, calcium, serum uric acid, lactate dehydrogenase) and diagnoses,chemotherapy and treatments were noted.Results: Of the 32 patientswho were included in the study, 17 were male and 15 were female. The averageage of the patients was found as 62,06 ± 12,10 (35-86) years. Hematologicmalignancy was detected in the etiology of11 of the TLS cases and solid tumor was detected in 21 of the TLS cases. Atotal of 12 (37.5%) patients had spontaneous TLS (5 in haematologicalmalignancy and 7 in solid tumor). Hyperpotassaemia 50%, hypocalcaemia 46.9%,hyperphosphatemia, hyperuricemia and acute kidney damage was present in allpatients. Mortality rate was found as 40.6%.Conclusions: Inour study, spontaneous TLS was detected at a high rate. In addition, themortality rate was also high. Early diagnosis and urgent treatment should beplanned to avoid mortalities.
KW  - Tumor lysis syndrome
KW  - malignancy
KW  - hyperuricemia
KW  - acute renal damage
N2  - Amaç:Tümör lizis sendromu (TLS), tümörhücrelerinin hızlı bir şekilde yıkılmasıyla ortaya çıkan ve yaşamı tehditedebilen metabolik bozukluklarla seyreden klinik bir tablodur.Çalışmamızdaki amaç TLS olguların etyolojik nedenleri, tanı ve tedavilerini değerlendirmektir.Yöntem:Çalışma Ocak 2015 ile Aralık 2017tarihleri arasındaKahramanmaras Necip Fazıl Şehir[HT1]hastanesindeyapıldı. Çalışmaya, TLS tanısı konan toplam 32 hasta alındı. Hastalarındosyaları taranarak laboratuvar değerleri (kan üre azotu, kreatinin, potasyum,fosfor, kalsiyum, serum ürik asit, laktat dehidrogenaz), tanıları, aldıklarıkemoterapi ve tedavileri not edildi.Bulgular:Çalışmaya alınan toplam 32 hastanın17’si erkek, 15’i bayandı. Hastaların ortalama yaşları 62,06±12,10 (35-86) olaraksaptandı. TLS olgularının 11’nin etiyolojisinde hematolojik malignensi, 21’indeise solid tümör saptandı. Toplam 12 (37,5%) hastada spontan TLS (5’ihematolojik malignensi ve 7’si solid tümör) tespit edildi. Hiperpotasemi 50%oranında, hipokalsemi 46,9% oranında, hiperfosfatemi, hiperürisemi ve akutböbrek hasarı ise hastaların tümünde mevcuttu. Mortalite oranı 40,6% olaraksaptandı.Sonuç:Çalışmamızda spontan TLS yüksek orandasaptandı. Ayrıca mortalite oranıda yüksekti. Mortaliteden kaçınmak için erkentanı ve acil tedavi planlanmalıdır.
CR  - 1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11.
CR  - 2. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leukemia& lymphoma 2003;44:77-83.
CR  - 3. Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, et al. Groupe de Rechercheen Réanimation Respiratoire et Onco-Hématologique (GRRR-OH). Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Rechercheen Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162:489-97.
CR  - 4. Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent ML, Martínez D, et al.  Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67-74.
CR  - 5. Mott FE, Esana A, Chakmakjian C, Herrington JD. Tumor lysis syndrome in solid tumors. Support Cancer Ther 2005;2:188–91.
CR  - 6. Vodopivec DM, Rubio JE, Fornoni A, Lenz O. An unusual presentation of tumor lysis syndrome in patient with advanced gastricadenocarcinoma: case report and literature review. Case Rep Med 2012;2012:468452.
CR  - 7. Goyal H, Sawhney H, Bekara S, Singla U. Spontaneous acute tumour lysis syndrome in gastric adenocarcinoma: a case report and literature review.J Gastrointest Cancer 2014;45:208-11.
CR  - 8. Weerasinghe C, Zaarour M, Arnaout S, Garcia G, Dhar M. Spontaneous Tumor Lysis Syndrome in Small-Cell Lung Cancer: A Rare Complication. World J Oncol 2015;6:464-71.
CR  - 9. Sommerhalder D, Takalkar AM, Shackelford R, Peddi P. Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review. Clin Case Rep 2017;5:2121-6.
CR  - 10. Harada S, Nagaharu K, Baba Y, Murata T, Mizuno T, Kawakami K. Spontaneous Tumor Lysis Syndrome in a Patient with a Dedifferentiated Endometrial Adenocarcinoma. Case Rep Oncol Med 2017;2017:5103145.
CR  - 11.  Singh A, Gupta S, Yim B, Thekkekara R. Tumor Lysis Syndrome in Multiple Myeloma: An Increasingly Recognized Risk-A Report of Seven Cases. Indian J Hematol Blood Transfus 2017;33:41-4.
CR  - 12. Sezer O, Vesole DH, Singhal S, Richardson P, Stadtmauer E, Jakob C, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006;7:233-5.
CR  - 13. Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, Hasan S, et al. Tumor lysis syndrome: a systematic review of case series and case reports.Postgrad. 2012 ;124:92-101.
CR  - 14. Caravaca-Fontán F, Martínez-Sáez O, Pampa-Saico S, Olmedo ME, Gomis A, Garrido P. Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis. Med Clin (Barc) 2017;148:121-4.
CR  - 15. Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 2010;51: 221–7.
CR  - 16. Darmon M, Vincent F, Canet E, Mokart D, Pène F, Kouatchet A,  et al. Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Rechercheen Réanimation Respiratoireen Onco-Hématologie. Nephrol Dial Transplant. 2015;30:2006-13.
CR  - 17. Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008;93:1877–85.
CR  - 18. Goldman SC. Rasburicase: potential role in managing tumour lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003;3:429-33.
UR  - https://doi.org/10.7197/223.vi.460369
L1  - https://dergipark.org.tr/en/download/article-file/681751
ER  -